Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion positive non small cell lung cancer.pdf (2.4 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-06-03

Llicència de publicació

cc-by-nc-nd (c) Eli Lilly and Company, 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/222240

Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1080/14796694.2025.2508132

Resum

AimsSelpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer.Materials & methodsEfficacy and safety were compared using matching-adjusted indirect comparison.ResultsMedian progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53-0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60-1.09). Grade >= 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively.ConclusionOutcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade >= 3 TRAEs.

Matèries

Medicaments antineoplàstics, Oncologia

Matèries (anglès)

Antineoplastic agents, Oncology

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

HOCHMAIR, Maximilian, et al. Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer. Future Oncology. 2025. Vol. 21, num. 15, pags. 1867-1878. ISSN 1744-8301. [consulted: 3 of August of 2026]. Available at: https://hdl.handle.net/2445/222240

Exportar metadades

JSON - METS

Compartir registre